King Pharmaceuticals has ended its alliance with Palatin
Technologies, shortly after regulators raised 'serious concerns'
over the first-in-class erectile dysfunction drug which was the
subject of the collaboration.
A more spontaneous future for sufferers of erectile dysfunction has
been heralded by the successful completion of a Phase I clinical
trial of a new gene therapy which could provide six months' effect
with a single dose.
Vectura, a UK biotechnology company which is developing an inhaled
alternative to orally acting impotence drugs such as Pfizer's
Viagra (sildenafil), has announced plans to float on the London
The next generation of orally-active erectile dysfunction (ED)
drugs took a step closer as researchers isolated a receptor that
could be used as a target of drug treatment without the side
effects associated with the only approved...
The US Food and Drug Administration (FDA) approved 15 New Molecular
Entities in the current year to 30 September, 2003, setting the
stage to outpace last year's registrations by nearly 20 per cent,
says a report from Cutting...